Yvonne Greenstreet is the CEO of Alnylam Pharmaceuticals.
The chief executive of Alnylam Pharmaceuticals Inc. has once again reported an increase in her total compensation.
CEO Yvonne Greenstreet saw her total compensation reach nearly $11.5 million in 2024, per a new securities filing. That’s up from almost $8.9 million in 2023 and around $4.59 million in 2022.
Stream NBC10 Boston news for free, 24/7, wherever you are.
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox with our News Headlines newsletter.
Copyright Boston Business Journal
